Z
Zhendong Chen
Researcher at Anhui Medical University
Publications - 76
Citations - 7291
Zhendong Chen is an academic researcher from Anhui Medical University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 13, co-authored 40 publications receiving 5077 citations.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Ann-Lii Cheng,Yoon-Koo Kang,Zhendong Chen,Chao Jung Tsao,Shukui Qin,Jun Suk Kim,Rongcheng Luo,Jifeng Feng,Sheng-Long Ye,Tsai Sheng Yang,Jianming Xu,Yan Sun,Houjie Liang,Jiwei Liu,Jiejun Wang,Won Young Tak,Hongming Pan,Karin Burock,Jessie Zou,D. Voliotis,Zhongzhen Guan +20 more
TL;DR: Sorafenib is effective for the treatment of advanced hepatocellular carcinoma in patients from the Asia-Pacific region, and is well tolerated.
Journal ArticleDOI
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Zhenggang Ren,Jianming Xu,Yuxian Bai,Aibing Xu,Shundong Cang,Chengyou Du,Qiu Li,Yinying Lu,Yajin Chen,Yabing Guo,Zhendong Chen,Baorui Liu,Weidong Jia,Jian Wu,Junye Wang,Guoliang Shao,Bixiang Zhang,Yunfeng Shan,Zhiqiang Meng,Jianbing Wu,Shanzhi Gu,Wei Yang,Chao Liu,Xuetao Shi,Zhenyuan Gao,Tao Yin,Jiuwei Cui,Ming Huang,Baocai Xing,Yilei Mao,Gao-Jun Teng,Yanru Qin,Jinhai Wang,Feng Xia,Guowen Yin,Yong Yang,Mingxia Chen,Yan Wang,Hui Zhou,Jia Fan +39 more
TL;DR: The phase 2-3 ORIENT-32 study as discussed by the authors compared sintilimab (a PD-1 inhibitor) plus IBI305, a bevacizumab biosimilar, versus sorafenib as a first-line treatment for unresectable HBV-associated hepatocellular carcinoma.
Journal ArticleDOI
Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial
Shukui Qin,Zhenggang Ren,Zhiqiang Meng,Zhendong Chen,Xiaoli Chai,Jianping Xiong,Yuxian Bai,Lin Yang,Hong Zhu,Weijia Fang,Xiaoyan Lin,Xiaoming Chen,Enxiao Li,Linna Wang,Chunxia Chen,Jianjun Zou +15 more
TL;DR: Camrelizumab showed antitumour activity in pretreated Chinese patients with advanced hepatocellular carcinoma, with manageable toxicities, and might represent a new treatment option for these patients.
Journal ArticleDOI
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study.
Jing Huang,Jianming Xu,Chen Yun,Wu Zhuang,Yiping Zhang,Zhendong Chen,Jia Chen,Helong Zhang,Zuoxing Niu,Qingxia Fan,Lizhu Lin,Kangsheng Gu,Ying Liu,Yi Ba,Zhanhui Miao,Xiaodong Jiang,Ming Zeng,Jianhua Chen,Zhichao Fu,Lu Gan,Jun Wang,Xianbao Zhan,Tianshu Liu,Zhiping Li,Lin Shen,Yongqian Shu,Tao Zhang,Qing Yang,Jianjun Zou,Suxia Luo,Feng Peng,Gang Wu,Nong Xu,Lin Zhao,Dong Ma,Shukui Qin,Wei Ren,Enxiao Li,H. Lu,Yueyin Pan,Jianping Xiong,Ying Yuan,Yuxian Bai,Lei Chen,Yi Hu,Li Zhang,Yong Gao +46 more
TL;DR: Second-line camrelizumab significantly improved overall survival in patients with advanced or metastatic oesophageal squamous cell carcinoma compared with chemotherapy, with a manageable safety profile.
Journal ArticleDOI
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia–Pacific trial
Ann-Lii Cheng,Zhongzhen Guan,Zhendong Chen,Chao Jung Tsao,Shukui Qin,Jun Suk Kim,Tsai Sheng Yang,Won Young Tak,Hongming Pan,Shiying Yu,Jianming Xu,Fang Fang,Jessie Zou,Giuseppe Lentini,D. Voliotis,Yoon-Koo Kang +15 more
TL;DR: Experimental analyses suggest that sorafenib is effective for patients from the AP region with advanced HCC, irrespective of baseline status, and the efficacy and safety profiles in the subpopulations described were comparable with those in the overall study population.